MET and prostate carcinoma: Surprisingly, (−)-oleocanthal did not show a significant inhibitory effect on c-Met activation in this prostate cancer model, corroborating the results of the scattering assay and suggesting that (−)-oleocanthal would interrupt c-Met signaling in a cell type-specific manner (Figure 7B).